120 related articles for article (PubMed ID: 8695233)
1. Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma.
Reinhold U; Bruske T; Kreysel HW
Eur J Cancer; 1996 Jan; 32A(1):180. PubMed ID: 8695233
[No Abstract] [Full Text] [Related]
2. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
4. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
Vuoristo MS
Melanoma Res; 1996 Aug; 6(4):331-6. PubMed ID: 8873054
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
[TBL] [Abstract][Full Text] [Related]
6. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
[TBL] [Abstract][Full Text] [Related]
7. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T
J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
[TBL] [Abstract][Full Text] [Related]
8. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
[TBL] [Abstract][Full Text] [Related]
9. Intermittent interferon and polychemotherapy in metastatic melanoma.
Vuoristo MS; Gröhn P; Kellokumpu-Lehtinen P; Kumpulainen E; Turunen M; Korpela M; Joensuu H; Tiusanen K; Nevantaus A
J Cancer Res Clin Oncol; 1995; 121(3):175-80. PubMed ID: 7536196
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
Vuoristo M; Gröhn P; Kumpulainen E; Korpela M
Eur J Cancer; 1994; 30A(3):420. PubMed ID: 7515632
[No Abstract] [Full Text] [Related]
11. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.
Hahka-Kemppinen M; Muhonen T; Virolainen M; Jekunen A; Asko-Seljavaara S; Pyrhönen S
Br J Dermatol; 1995 Jun; 132(6):973-7. PubMed ID: 7544996
[TBL] [Abstract][Full Text] [Related]
12. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
York RM; Foltz AT
Cancer; 1988 Jun; 61(11):2183-6. PubMed ID: 2452681
[TBL] [Abstract][Full Text] [Related]
13. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma.
Muhonen T; Hahka-Kemppinen M; Pakkala S; Pyrhönen S
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):67-73. PubMed ID: 7509188
[TBL] [Abstract][Full Text] [Related]
14. Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
Mattila K; Raanta P; Lahtela V; Pyrhönen S; Koskivuo I; Vihinen P
Anticancer Res; 2018 Nov; 38(11):6393-6397. PubMed ID: 30396963
[TBL] [Abstract][Full Text] [Related]
15. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
[TBL] [Abstract][Full Text] [Related]
16. Long-term progression-free survival in metastatic uveal melanoma after chemoimmunotherapy and consolidation thermoablation.
Al-Jamal RT; Eskelin S; Pyrhönen S; Kivelä T
Acta Oncol; 2009; 48(3):476-9. PubMed ID: 19031163
[No Abstract] [Full Text] [Related]
17. DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma.
Hahka-Kemppinen M; Muhonen T; Nordling S; Pyrhönen S
Melanoma Res; 1997 Aug; 7(4):329-34. PubMed ID: 9293483
[TBL] [Abstract][Full Text] [Related]
18. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Kähäri VM; Pyrhönen S
Int J Cancer; 2002 Feb; 97(4):432-8. PubMed ID: 11802203
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay--can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma?
Hahka-Kemppinen M; Muhonen T; Kangas L; Pyrhönen S
Melanoma Res; 1996 Jun; 6(3):215-21. PubMed ID: 8819124
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy of malignant melanoma. A pilot study.
Hansson J; Ringborg U; Lagerlöf B; Strander H
Am J Clin Oncol; 1985 Feb; 8(1):47-50. PubMed ID: 3993625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
